Effect of intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris

Archives of Dermatology

Volumn 144, Issue 12, 2008, Pages 1621-1624

  Green, Michelle G ^a   Bystryn, Jean Claude ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; DAPSONE; DESMOGLEIN 1 ANTIBODY; DESMOGLEIN 3 ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G4; PREDNISONE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LUNG ASPERGILLOSIS; MALE; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; DESMOGLEIN 1; DESMOGLEIN 3; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; PEMPHIGUS;

EID: 58049202056     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2008.503     Document Type: Article

References (10)

1. Bystryn JC, Jiao D. IVIG selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity. 2006;39(7):601-607.
2. Futei Y, Amagai M, Ishii K, Kuroda-Kinoshita K, Ohya K, Nishikawa T. Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus. J Dermatol Sci. 2001;26(1):55-61.
3. Bhol K, Mohimen A, Ahmed AR. Correlation of subclasses of IgG with disease activity in pemphigus vulgaris. Dermatology. 1994;189(suppl 1):85-89.
4. Bhol K, Natarajan K, Nagarwalla N, Mohimen A, Aoki V, Ahmed R. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc Natl Acad Sci U S A. 1995;92(11):5239-5243.
5. Hacker MK, Janson M, Fairley JA, Lin M. Isotypes and antigenic profiles of pemphigus foliaceous and pemphigus vulgaris autoantibodies. Clin Immunol. 2002;105(1):64-74.
6. Ishii K, Amagai M, Hall RP, et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol. 1997;159(4):2010-2017.
7. Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol. 2002;47(3):358-363.
8. Herzog S, Schmidt E, Goebeler M, Bröcker EB, Zillikens D. Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins. Acta Derm Venereol. 2004;84(1):48-52.
9. Sami N, Bhol KC, Ahmed RA. Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. Eur J Dermatol. 2003;13(4):377-381.
10. Bystryn JC, Rudolph JL. IVIG treatment of pemphigus: how it works and how to use it. J Invest Dermatol. 2005;125(6):1093-1098.